Tempest Therapeutics is a biotechnology company founded in 2017 with a focus on developing small molecule therapeutics to target anti-tumor immunity pathways for the treatment of cancer. The company's founding history involves its establishment in 2017with the goal of leveraging insights into the tumor microenvironment and immunobiology to develop innovative cancer therapies.

Headquartered in South San Francisco, California, United States, Tempest Therapeuticsoperates in the heart of the biotechnology hub, allowing it to tap into the region's richecosystem of scientific expertise, resources, and collaborations. This strategic location provides the company with access to top talent, cutting-edge research facilities, and partnerships with other biotech and pharmaceutical companies, fostering an environment conducive to innovation and advancement in cancer immunotherapy.

Tempest Therapeutics' commitment to addressing the unmet medical needs of cancer patients drives its research and development efforts. The company's lead product candidate, TPST-1495, targets the Siglec-15 (S15) pathway, a promising immunotherapytarget in oncology. Through its dedication to advancing the field of cancer immunotherapy, Tempest Therapeutics aims to bring new treatment options to patients and make a meaningful impact in the fight against cancer.